Table 4.

Univariate and multivariate analysis related to PFS and OS in 144 mCRC treated with anti-EGFR mAb cetuximab. p-Value of ≤0.05 was considered significant.

Variables	Progression Free Survival (PFS)
	Univariate			Multivariate
	HR	95% CI	p-Value	HR	95% CI	p-Value
HER2 (Membranous)	2.097	1.242–3.542	0.006	2.560	1.295–5.059	0.007
HER2 (Cytoplasmic)	0.518	0.305–0.879	0.015	0.367	0.185–0.728	0.004
HER3 (3+)	2.307	0.986–5.398	0.054	-	-	NS
	Overall Survival (OS)
	Univariate			Multivariate
	HR	95% CI	p-Value	HR	95% CI	p-Value
wtEGFR (Cytoplasmic)	3.584	1.455–8.826	0.006	3.822	1.446–10.103	0.007
wtEGFR (>20%)	3.084	1.274–7.464	0.013	2.914	1.064–7.986	0.038
wtEGFR (>50%)	4.473	1.309–15.287	0.017	4.810	1.320–17.524	0.017
HER2	0.213	0.62–0.734	0.014	-	-	NS

HR, hazard ratio; CI, confidence interval; NS, Not significant.